Influence of the degree of donor bone marrow hyperplasia on patient clinical outcomes after allogeneic hematopoietic stem cell transplantation  

作　　者：Feifei Tang Xiaodong Mo Xiaohui Zhang Yu Wang Chenhua Yan Yuhong Chen Huan Chen Wei Han Yao Chen Fengrong Wang Jingzhi Wang Yuqian Sun Yuanyuan Zhang Kaiyan Liu Xiaojun Huang Lanping Xu 

机构地区：[1]Peking University People's Hospital,Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,China [2]Peking-Tsinghua Center for Life Sciences,Peking University,Beijing 100871,China

出　　处：《Science China(Life Sciences)》2020年第1期138-147,共10页中国科学(生命科学英文版)

基　　金：supported by the National Natural Science Foundation of China(81670167);the Foundation for Innovative Research Groups of the National Natural Science Foundation of China(81621001);sponsored by the Fund for Fostering Young Scholars of Peking University Health Science Center(BMU2017PY010)

摘　　要：This study evaluated the influence of the degree of donor bone marrow(BM)hyperplasia on patient clinical outcomes after allogeneic hematopoietic stem cell transplantation(allo-HSCT).Twelve patients received allo-HSCT from hypoplastic BM donors between January 2010 and December 2017.Forty-eight patients whose donors demonstrated BM hyperplasia were selected using a propensity score matching method(1:4).Primary graft failure including poor graft function and graft rejection did not occur in two groups.In BM hypoplasia and hyperplasia groups,the cumulative incidence(CI)of neutrophil engraftment at day 28(91.7%vs.93.8%,P=0.75),platelet engraftment at day 150(83.3%vs.93.8%,P=0.48),the median time to myeloid engraftment(14 days vs.14 days,P=0.85)and platelet engraftment(14 days vs.14 days,P=0.85)were comparable.The 3-year progression-free survival,overall survival,CI of non-relapse mortality and relapse were 67.8%vs.71.7%(P=0.98),69.8%vs.77.8%(P=0.69),18.5%vs.13.6%(P=0.66),and 10.2%vs.10.4%(P=0.82),respectively.In multivariate analysis,donor BM hypoplasia did not affect patient clinical outcomes after allo-HSCT.If patients have no other suitable donor,a donor with BM hypoplasia can be used for patients receiving allo-HSCT if the donor Complete Blood Count and other examinations are normal.This study evaluated the influence of the degree of donor bone marrow(BM) hyperplasia on patient clinical outcomes after allogeneic hematopoietic stem cell transplantation(allo-HSCT). Twelve patients received allo-HSCT from hypoplastic BM donors between January 2010 and December 2017. Forty-eight patients whose donors demonstrated BM hyperplasia were selected using a propensity score matching method(1:4). Primary graft failure including poor graft function and graft rejection did not occur in two groups. In BM hypoplasia and hyperplasia groups,the cumulative incidence(CI) of neutrophil engraftment at day 28(91.7% vs. 93.8%, P=0.75), platelet engraftment at day 150(83.3% vs. 93.8%, P=0.48), the median time to myeloid engraftment(14 days vs. 14 days, P=0.85) and platelet engraftment(14 days vs. 14 days, P=0.85) were comparable. The 3-year progression-free survival, overall survival, CI of non-relapse mortality and relapse were 67.8% vs. 71.7%(P=0.98), 69.8% vs.77.8%(P=0.69), 18.5% vs. 13.6%(P=0.66), and 10.2% vs. 10.4%(P=0.82), respectively. In multivariate analysis, donor BM hypoplasia did not affect patient clinical outcomes after allo-HSCT. If patients have no other suitable donor, a donor with BM hypoplasia can be used for patients receiving allo-HSCT if the donor Complete Blood Count and other examinations are normal.

关 键 词：bone marrow aspirate HYPOPLASIA hyperplasic normal donor allogeneic hematopoietic stem cell transplantation 

分 类 号：R457.7[医药卫生—治疗学]